Advertisement
Advertisement
U.S. markets close in 1 hour 42 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Syros Pharmaceuticals, Inc. (SYRS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.9033-0.0089 (-0.98%)
As of 02:18PM EDT. Market open.
Advertisement

Syros Pharmaceuticals, Inc.

35 CambridgePark Drive
4th Floor
Cambridge, MA 02140
United States
617 744 1340
https://www.syros.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees124

Key Executives

NameTitlePayExercisedYear Born
Dr. Nancy A. Simonian M.D.Pres, CEO & Director939.4kN/A1961
Dr. Richard A. Young Ph.D.Scientific Founder, Member of Scientific Advisory Board & Director50kN/A1954
Mr. Jason HaasChief Financial Officer457.22kN/A1968
Dr. David A. Roth M.D.Chief Medical Officer668.12kN/A1963
Dr. James E. Bradner M.D.FounderN/AN/A1972
Dr. Nathanael S. Gray Ph.D.Scientific Founder & Member of Scientific Advisory BoardN/AN/AN/A
Mr. Gerald E. Quirk Esq., J.D.Sr. AdvisorN/AN/A1968
Dr. Eric R. Olson Ph.D.Chief Scientific OfficerN/AN/A1958
Courtney SolbergMang. of Corp. Communications and Investor RelationsN/AN/AN/A
Dr. Christian C. Fritz Ph.D.Head of BiologyN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Syros Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 7. The pillar scores are Audit: 6; Board: 7; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement